Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Acute leukaemia, Acute myeloid leukaemia (AML), Blood cancers, Children's cancers, Leukaemia, Myelodysplastic syndrome (MDS)
Closed
Phase 3
This study is to find how many doses of gemtuzumab ozogamicin (Mylotarg) to give with chemotherapy for children with acute myeloid leukaemia (AML).
This summary is 1 of 3 summaries of the MyeChild01 trial.
To take part in this study you must have agreed to join the improving chemotherapy for AML part of the MyeChild01 trial.
Further in your treatment if you are suitable, you might be asked to take part in the stem cell transplant part of the trial. .
Cancer Research UK supports this study and the MyeChild01 trial.
This study is for children and young people who haven’t reached their 18th birthday. We use the term ‘you’ in the summary but if you are a parent we are referring to your child.
Recruitment start: 29 April 2016
Recruitment end: 23 October 2023
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Brenda Gibson
Cancer Research UK
Pfizer
University of Birmingham
This is Cancer Research UK trial number CRUK/14/013.
You can read more information about the trial on the MyeChild01 website.
Last reviewed: 30 July 2024
CRUK internal database number: 14213
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
